Published in Regul Toxicol Pharmacol on April 01, 2002
Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation. J Toxicol (2012) 0.90
A Workflow for Global Sensitivity Analysis of PBPK Models. Front Pharmacol (2011) 0.87
Using a pharmacokinetic model to relate an individual's susceptibility to alcohol dependence to genotypes. Hum Hered (2010) 0.77
The application of global sensitivity analysis in the development of a physiologically based pharmacokinetic model for m-xylene and ethanol co-exposure in humans. Front Pharmacol (2015) 0.77
Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol (1981) 3.07
Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med (1982) 2.72
Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr (1977) 2.43
Amiodarone pharmacokinetics. Am Heart J (1983) 2.42
Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol (1981) 2.38
Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility. Br J Clin Pharmacol (1981) 2.08
Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties, and anesthetic activity. Anesthesiology (1970) 1.71
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol (1992) 1.71
Polymorphic hydroxylation of debrisoquine. Lancet (1977) 1.69
Plasma concentrations of local anaesthetics after interscalene brachial plexus block. Br J Anaesth (1977) 1.66
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. Br J Clin Pharmacol (1985) 1.64
Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. Br J Cancer (2011) 1.62
A six-year evaluation of methadone prescribing practices at a substance misuse treatment centre in the UK. J Clin Pharm Ther (2006) 1.58
Lack of effect of atenolol on antipyrine clearance. Br J Clin Pharmacol (1982) 1.51
Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet (1979) 1.47
Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine. CPT Pharmacometrics Syst Pharmacol (2013) 1.44
Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics (1996) 1.41
Gerontokinetics--a reappraisal. Br J Clin Pharmacol (1992) 1.41
Towards a standardized anaesthetic state using enflurane and morphine. Br J Anaesth (1991) 1.39
Meperidine kinetics in man. Intravenous injection in surgical patients and volunteers. Clin Pharmacol Ther (1975) 1.39
Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol (1997) 1.37
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther (1988) 1.37
Measurement of the renal clearance of drugs. Br J Clin Pharmacol (1981) 1.35
Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther (1986) 1.32
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol (1986) 1.29
Lignocaine and indocyanine green kinetics in patients following myocardial infarction. Br J Clin Pharmacol (1980) 1.28
Why hypertensive patients vary in their response to oral debrisoquine. Br Med J (1977) 1.25
Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica (2006) 1.24
Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos (1997) 1.23
Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther (1983) 1.22
Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol (1999) 1.21
The disposition of debrisoquine in hypertensive patients. Br J Clin Pharmacol (1978) 1.16
Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol (2001) 1.15
Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica (2007) 1.12
Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol (2003) 1.11
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther (1996) 1.11
Lactic acidosis during metformin treatment in an elderly diabetic patient with impaired renal function. Acta Med Scand (1981) 1.11
Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) (2006) 1.10
Pharmacokinetic aspects of intravenous regional anesthesia. Anesthesiology (1971) 1.10
Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos (2004) 1.10
Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin. Clin Pharmacol Ther (1982) 1.08
Meperidine and other basic drugs: general method for their determination in plasma. J Pharm Sci (1974) 1.08
Routine detection and identification in urine of stimulants and other drugs, some of which may be used to modify performance in sport. J Pharm Pharmacol (1967) 1.08
Polymorphic metabolism of beta-adrenoceptor antagonists. Br J Clin Pharmacol (1984) 1.08
Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol (1985) 1.07
Systemic absorption of mepivacaine in commonly used regional block procedures. Anesthesiology (1972) 1.06
Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica (2004) 1.05
Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem (1995) 1.05
Pharmacokinetics of local anaesthetics. Br J Anaesth (1986) 1.04
Pethidine revisited: plasma concentrations and effects after intramuscular injection. Br J Anaesth (1975) 1.04
Journal impact factors: a 'bioequivalence' issue? Br J Clin Pharmacol (2001) 1.04
Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf) (2007) 1.04
Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine. Br J Clin Pharmacol (1984) 1.03
Amiodarone pharmacokinetics. Br J Clin Pract Suppl (1986) 1.02
A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction. CPT Pharmacometrics Syst Pharmacol (2012) 1.02
The antitussive effect of dextromethorphan in relation to CYP2D6 activity. Br J Clin Pharmacol (1999) 1.01
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet (1986) 1.00
The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol (1997) 1.00
Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing. Br J Clin Pharmacol (1989) 0.99
Acebutolol in hypertension: relationships between drug concentration and effects. Eur J Clin Pharmacol (1978) 0.99
Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots. Br J Clin Pharmacol (1989) 0.99
Determination of metformin in biological samples. Br J Clin Pharmacol (1978) 0.98
A survey of fuzzy logic monitoring and control utilisation in medicine. Artif Intell Med (2001) 0.97
In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics (1999) 0.96
Backtracking booze with Bayes--the retrospective interpretation of blood alcohol data. Br J Clin Pharmacol (1991) 0.95
Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab (2009) 0.95
A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet (2014) 0.95
Disposition kinetics of ropivacaine in humans. Anesth Analg (1989) 0.95
Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs. J Pharm Pharmacol (1990) 0.94
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol (1984) 0.94
Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr Drug Metab (2010) 0.94
The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans. J Clin Endocrinol Metab (1997) 0.93
Bupivacaine hydrochloride: laboratory and clinical studies. Anesthesiology (1970) 0.93
Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica (2006) 0.92
Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol (1996) 0.92
Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings. Curr Drug Metab (2012) 0.92
Beeturia and the biological fate of beetroot pigments. Pharmacogenetics (1993) 0.91
Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. Br J Clin Pharmacol (2003) 0.91
Debrisoquine and mephenytoin oxidation in Sinhalese: a population study. Br J Clin Pharmacol (1994) 0.91
The effects of adding adrenaline to etidocaine and lignocaine in extradural anaesthesia II: Pharmacokinetics. Br J Anaesth (1976) 0.91
Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450. Carcinogenesis (1994) 0.91
A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab (2006) 0.91
Development of CYP2D6 and CYP3A4 in the first year of life. Clin Pharmacol Ther (2008) 0.90
Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci (2011) 0.90
A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol (2003) 0.90